Press Releases
Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91
Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
Lupin Bioresearch Center Receives Zero Observations from U.S. FDA After Successful Inspection and Assessment
Media

Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.
